SUBCUTANEOUS DRUG ADMINISTRATION DEVICE
The flexible sleeve and protective element combination in subcutaneous drug delivery devices address water and sweat ingress issues, maintaining device functionality and integrity by ensuring watertight sealing at the injection needle exit point.
Patent Information
- Application Number
- FR2023013437
- Authority / Receiving Office
- FR · FR
- Patent Type
- Utility models
- Current Assignee / Owner
- Priority Date
- 2022-12-01
- Filing Date
- 2023-12-01
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2033-12-01
AI Technical Summary
Existing subcutaneous drug delivery devices are vulnerable to water and sweat ingress, leading to mechanical and electronic failures, especially at the injection needle exit point, compromising their functionality during daily activities.
A flexible sleeve associated with a protective element around the injection needle, moving synchronously to ensure watertight sealing at the needle exit point, combined with a base having a through hole for needle movement, and a silicone membrane for continuous coverage.
Prevents ingress of water and powders, maintaining device integrity and functionality during prolonged wear, ensuring seamless operation despite exposure to moisture and daily activities.
Smart Images

Figure 00000028_0000 
Figure 00000029_0000 
Figure 00000030_0000
Abstract
Description
Title of the invention: DEVICE FOR SUBCUTANEOUS ADMINISTRATION OF A DRUG Technical field of the invention
[0001] The present invention relates to a device for subcutaneous administration of a drug.
[0002] In particular, the device of the present invention falls within the category of "infusion pumps" as defined by the FDA (US Food and Drug Administration) and relates, more specifically, to a wearable device, that is, one configured to be applied to a patient's body to allow the subcutaneous administration of a predetermined dose of medication. The application of the device to the patient's body is performed by a user, for example, a physician or nurse, or by the patient themselves. Technical context
[0003] Examples of administration devices of the type discussed above are described in EP 3439715B1 and WO 2020 / 128821A1.
[0004] In all body-worn administration devices, the drug is initially contained in a cartridge housed inside the device and is transferred into the patient's body via a fluidic pathway.
[0005] In the present application, the term "fluidic path" is used to designate any element or set of elements which is configured to be connected, at a first end thereof, to the cartridge housed inside the delivery device and comprising, at an end thereof opposite to the first end mentioned above, an injection needle intended to be inserted into the patient's body to allow the transfer of the drug from the cartridge to the patient's body.
[0006] Typically, the cartridge includes a cylindrical container, made of a plastic or glass material, a piston that can slide inside the container to push the drug out of the container and a pierceable septum that ensures the sterility of the container until the start of the therapy administration.
[0007] Typically, the fluidic path includes a drilling needle configured to pierce the pierceable septum of the cartridge and a flexible tube that puts the drilling needle into fluidic communication with the injection needle.
[0008] In such devices, the cartridge container is kept closed by the pierceable septum until drug administration is required. When such administration is required, the piercing needle pierces the pierceable septum and opens the fluid pathway, allowing the drug to reach the patient by passing through first through the piercing needle, then through the flexible tube and finally through the injection needle, due to the thrust exerted by the piston on the drug inside the container.
[0009] Obviously, the administration of the drug to the patient takes place after the insertion of the injection needle into the patient's body.
[0010] Such insertion occurs following the activation of a displacement mechanism configured to move the injection needle between a rest position in which the injection needle is entirely disposed inside the device and an injection position in which the injection needle protrudes from the device and penetrates the patient's skin.
[0011] The displacement mechanism can also be configured to extract the injection needle from the patient's skin at the end of the therapy administration by bringing it back inside the device.
[0012] The Applicant observed that in applications where continuous drug delivery is required, subcutaneous delivery devices must be worn by the patient for extended periods. Therefore, these devices must be waterproof to avoid interfering with the patient's daily life during activities such as showering, bathing, playing sports, swimming, etc. Indeed, if water, or even sweat, penetrates the device, the electronic and mechanical components inside could malfunction or break down.
[0013] The Applicant has examined all critical points where water and / or sweat may enter the device and has verified that the most critical point in terms of impermeability is the one in which the through-opening is provided through which the injection needle exits the device for the administration of the therapy.
[0014] WO 2021 / 252971A2 describes the use of a watertight barrier positioned above the through opening mentioned above.
[0015] US 2020 / 0222624A1 and US 2013 / 0060233A1 describe the use of a membrane extending inside the device around the injection needle when the needle is fully arranged within the device. The membrane maintains a sterile environment around the injection needle. When the injection needle exits the device, the membrane is folded like bellows inside the device.
[0016] The Applicant observed that many devices are conveniently equipped with protective elements arranged around the through-hole through which the injection needle exits for therapy administration. These protective elements are movable between a retracted position in which they are arranged inside the device and an extended position in which they are extracted from the device to be arranged around the injection needle when the device is removed from the patient's skin to protect the patient from accidental contact with the injection needle at the end of therapy administration. Examples of devices of the type described above are disclosed in WO 2002 / 02165A2 and US 10881811B2.
[0017] The Applicant assumes that, even in devices equipped with protective elements, appropriate measures should be taken to prevent the entry into the device of water, sweat and more generally of powders and liquids.
[0018] The technical problem solved by the present invention is therefore to provide a suitable solution to prevent the entry of water, sweat and more generally powders and liquids into devices equipped with protective elements which protrude from the device when the device is not applied to the patient's skin and which are housed in the device when the device is applied to the patient's skin.
[0019] The Applicant thought that this technical problem could be solved by arranging around the protective element a flexible sleeve capable of moving in synchronization with the protective element and by associating this flexible sleeve with the device in a watertight manner, and therefore also in a powder-tight manner. Summary of the invention
[0020] The present invention therefore relates to a device for subcutaneous administration of a drug, comprising: - an injection needle configured to inject the drug into a patient when the device is applied to the patient's skin, the injection needle being movable between a resting position in which the injection needle is entirely disposed inside the device and an injection position in which the injection needle protrudes at least partially from the device through a through-opening in the device; - a protective element arranged around the injection needle and movable between a first operating position in which the protective element protrudes from the device and a second operating position in which the protective element does not protrude from the device; - a flexible sleeve associated in a watertight manner with the device around said through opening and associated in one piece with the protective element.
[0021] By being attached as a single unit to the protective element, the flexible sleeve moves with the protective element between the first operating position mentioned above, in which the flexible sleeve and the protective element extend outside the device, and the second operating position as mentioned above, in which the flexible sleeve and the protective element are housed inside the device. Therefore, by joining the flexible sleeve to the device around the protective element in such a way as to be watertight, the device's impermeability and also its seal against powders at the through-hole through which the injection needle exits for therapy administration are ensured.
[0022] Preferred features of the device of the invention are described below. Each of these features can be provided individually or in combination with the others.
[0023] Preferably, the protective element includes a base with a through hole to allow the injection needle to pass through during the movement of the injection needle between the rest position and the injection position.
[0024] Preferably, said base includes a raised edge that defines a recess in the protective element to house the tip of the injection needle both when the protective element is in the second operating position and the injection needle is in the rest position, and when the protective element is in the first operating position and the injection needle is in the injection position. The raised edge surrounds the tip of the injection needle and prevents the user from coming into contact with the tip if the injection needle is outside the device and the device is not applied to the patient's skin.
[0025] Preferably, the flexible sleeve is associated in one piece with said base.
[0026] Preferably, the flexible sleeve is defined by a membrane having a surface internal which is associated in one piece with the external surface of said base.
[0027] Preferably, the membrane is of the bellows type and has a substantially conical or frustoconical shape. In this way, the membrane can be folded telescopically inside the device when the device is applied to the patient's skin, thus occupying an extremely limited space, contributing to the device's compactness.
[0028] In an optional embodiment, the flexible sleeve is not configured to close the through hole in the base of the protective element. In this case, said through hole is sealed by a pierceable septum configured to be pierced by the injection needle when the injection needle moves from the rest position to the injection position.
[0029] Preferably, the flexible sleeve has a base surface associated in one piece with the base of said protective element.
[0030] More preferably, the base surface of the flexible sleeve covers the through hole in the base of the protective element and can be pierced by the injection needle when the injection needle moves from the rest position to the position of injection. In this case, the flexible sleeve continuously covers the protective element, which also covers the through-hole of the device through which the injection needle exits. It is this same injection needle that pierces the base surface of the flexible sleeve as it exits the protective element and, consequently, the flexible sleeve. Therefore, there is no need to compensate for any dimensional differences between the through-hole and the septum. Furthermore, in this case, the flexible sleeve, in addition to ensuring a seal at the through-hole created by the injection needle, retains any drops of medication released by the device before administration.
[0031] Preferably, the flexible sleeve is entirely disposed inside the device when the protective element is in its second operating position, so as not to be bulky when the device is applied to the patient's skin.
[0032] Preferably, the device includes a compression ring welded to an application surface of the device at the level of said through opening.
[0033] Preferably, said flexible sleeve includes an annular end portion interposed between said application surface and said compression ring. The latter thus firmly compresses the flexible sleeve onto the device. Consequently, the desired seal at the through-hole of the device is achieved due to the compression of the annular end portion onto the application surface of the device by the compression ring.
[0034] Preferably, said compression ring is welded by ultrasonic welding.
[0035] Preferably, said flexible sleeve is made of a medical-grade silicone material. Brief description of the figures
[0036] Other features and advantages of the present invention will become clearer upon reading the following detailed description of preferred embodiments thereof, made with reference to the accompanying drawings and given by way of example only and not limitation. In these drawings:
[0037] [Fig.1] - [Fig.1] is a perspective view of a device according to the present invention;
[0038] [Fig.2] - [Fig.2] is an exploded perspective view of a first mode of realization lisation of a module of the device of the [Fig.l];
[0039] [Fig.3] - [Fig.3] is an exploded perspective view of another module of the device of the [Fig.l];
[0040] [Fig.4] - [Fig.4] is a perspective view from below of the device in [Fig.1] equipped with a patch;
[0041] [Fig.5] - [Fig.5] is a perspective view from below of the device in [Fig.4] after removing a protective layer from the patch;
[0042] [Fig.6] - [Fig.6] is a top cross-sectional view of the module of [Fig.2] in a initial configuration of the device in [Fig.1];
[0043] [Fig.7] - [Fig.7] is a perspective cross-sectional view of the device in [Fig.1] before being applied to the patient's skin;
[0044] [Fig.8] - [Fig.8] is a perspective cross-sectional view of the device of [Fig.1] just after it has been applied to the patient's skin;
[0045] [Fig.9] - [Fig.9] represents an enlargement of a detail of the module of [Fig.6] in a device operating configuration subsequent to that of [Fig.6]
[0046] [Fig. 10] - the [Fig. 10] is a side view in section of a part of the module of the [Fig.6] in an initial configuration of the device of the [Fig.1];
[0047] [Fig. 11] - [Fig. 11] is a side view in section of the part of [Fig. 10] in an operating configuration of the device subsequent to that of [Fig. 10] and corresponding to that of [Fig. 9];
[0048] [Fig. 12] - the [Fig. 12] is a side view in section of another detail of the module of the [Fig.6] in an initial configuration of the device of the [Fig.1];
[0049] [Fig. 13] - [Fig. 13] is a side view in section of the detail of [Fig. 12] in an operating configuration of the device subsequent to that of [Fig. 12] and corresponding to that of figures 9 and 11;
[0050] [Fig. 14] - [Fig. 14] is a perspective cross-sectional view of certain components of the module of [Fig. 6] in an operating configuration of the device subsequent to that of [Fig. 6] and corresponding to that of figures 9, 11 and 13;
[0051] [Fig. 15] and [Fig. 16] - Figures 15 and 16 are perspective views of certain components of a second embodiment of the device of the present invention in two subsequent operating configurations thereof;
[0052] [Fig. 17] - [Fig. 17] is a perspective cross-sectional view of some of the components of Figures 15 and 16 in an operating configuration of the device subsequent to that of [Fig. 16];
[0053] [Fig. 18], [Fig. 19], [Fig.20] and [Fig.21] - Figures 18 to 21 show an enlargement of another part of the module of [Fig.6] in four later operating configurations of the device of [Fig.1];
[0054] [Fig.22] - [Fig.22] is a cross-sectional side view of part of the device [Fig.1] in a device operating configuration subsequent to that of [Fig.8];
[0055] [Fig. 23] - [Fig. 23] is a cross-sectional side view of the device of [Fig. 1] in a possible operating configuration of the latter in which said device is not not applied to the patient's skin;
[0056] [Fig.24] - [Fig.24] is a perspective view of a component of the device [Fig.l];
[0057] [Fig.25] - [Fig.25] is a perspective view of part of a third mode of realization of the module of [Fig.2] when the device is not applied to the patient's skin;
[0058] [Fig.26] - [Fig.26] is a perspective view of the part of [Fig.25] just after having applied the device to the patient's skin;
[0059] [Fig.27] - [Fig.27] is a top view of part of [Fig.25] in the confi Functioning of the [Fig.26];
[0060] [Fig.28] - [Fig.28] is a perspective view of part of [Fig.25] in a device operating configuration subsequent to that of figures 26 and 27;
[0061] [Fig.29] - [Fig.29] is a top view of part of [Fig.25] in the confi Functioning of the [Fig.28];
[0062] [Fig. 30], [Fig. 31] and [Fig. 32] - Figures 30 to 32 are perspective views of the part of [Fig.25] in three device operating configurations subsequent to that of [Fig.28];
[0063] [Fig.33] - [Fig.33] is a side view in section of part of [Fig.25] in the operating configuration of the [Fig.26];
[0064] [Fig.34] - [Fig.34] is a side view in section of part of [Fig.25] in the operating configuration of the [Fig.32];
[0065] [Fig.35] - [Fig.35] is a time diagram relating to different stages of operation functions implemented by the device of the present invention during its use. Detailed description of the invention
[0066] In [Fig.1], a device of the type that can be worn on the person for the subcutaneous administration of a drug according to the present invention is indicated by the numerical reference 1.
[0067] Device 1 includes an administration module 2, shown in [Fig.2], and a control module 3, shown in [Fig.3].
[0068] Device 1 is obtained by mutually coupling the administration module 2 and the control module 3. This coupling is reversible, i.e. the two modules 2 and 3 can be decoupled after having been coupled.
[0069] One or more seals (not shown) are interposed between the administration module 2 and the control module 3 in order to ensure the sealing of the mutual coupling.
[0070] The administration module 2 is preferably disposable, whereas the module of Command module 3 is preferably reusable. In other words, administration module 2 is configured to be applied to the patient's body only once and for a specific period of time to administer the medication, completely or partially, in one or more successive injections, even if spaced out over time. Conversely, command module 3 can be used multiple times by occasionally coupling it with a new administration module 2.
[0071] As shown in [Fig. 3], the control module 3 comprises a lower body 4 and an upper cover 5 attached to the lower body 4, preferably by ultrasonic welding. In this case, ultrasonic welding is preferable to laser welding because the latter requires the use of transparent materials, which are not considered practical for the control module 3, since it can be customized with different colors and / or finishes.
[0072] A housing compartment 6 is defined between the lower body 4 and the upper cover 5. The housing compartment 6 contains a control unit 7, generally consisting of a printed circuit board and configured to control the administration of the drug from the administration module 2, a power supply battery 8 configured to power the control unit 7 and a motor 9 which drives a magnetic drive rotor 9a.
[0073] A plurality of electronic components and a hardware unit that supplies power to said electronic components are provided in the control module 3.
[0074] The control module 3 further includes a switch (not shown) configured to supply power to the control unit 7 and an activation button 3a. The patient activates the device 1 by pressing the activation button 3a.
[0075] As shown in [Fig. 2], the administration module 2 comprises a main body 11 and an intermediate cover 15 associated with the main body 11 and interposed between the main body 11 and the lower body 4 of the control module 3. Preferably, the intermediate cover 15 is welded to the main body 11 by laser welding. In this case, ultrasonic welding is preferable, since the administration module 2 is assembled with all the components described below already mounted on the main body 11, and the use of ultrasonic welding would risk activating these components.
[0076] A housing compartment 10 is defined between the main body 11 and the intermediate cover 15.
[0077] As shown in [Fig. 10], the main body 11 includes an application surface 12 configured to come into contact with the patient's body.
[0078] The application surface 12 is substantially flat and defines a plane P to rest on the patient's skin.
[0079] The application surface 12 includes a through opening 12a ([Fig.2]).
[0080] Referring again to [Fig.2], the housing compartment 10 is configured to house a plurality of components, including a cartridge 20 and a fluidic path 30.
[0081] The administration module 2 further includes an ignition magnet 2a and an NFC tag 2b on which a plurality of information is stored.
[0082] The cartridge 20 is disposed on the main body 11 and comprises a substantially cylindrical container 22, made of plastic or glass, containing the medication to be administered to a patient. A pierceable septum 24, which closes the container 22 and ensures its sterility until the device 1 is used, is arranged at one end 23 of the container 22. A piston 26 (shown in [Fig. 6]) can slide within the container 22 to administer the medication.
[0083] As shown in [Fig.6], the fluidic path 30 is also arranged on the main body 11 and is configured to be traversed by the drug during subcutaneous administration of the drug, allowing the transfer of the drug from the cartridge 20 to the patient's body.
[0084] The fluidic path 30 includes a piercing needle 32 configured to pierce the pierceable septum 24 (as illustrated for example in [Fig. 13]), an injection needle 34 configured to be inserted into the patient's body (as illustrated for example in [Fig. 22]), and a flexible tube 36 (illustrated for example in Figures 2 and 6) which puts the needles 32 and 34 mentioned above into fluidic communication.
[0085] In particular, as shown in Figures 2 and 6, the flexible tube 36 has an end portion 36a connected to a support member 42 which supports the piercing needle 32 and an opposite end portion 36b connected to a support member 62 which supports the injection needle 34.
[0086] With reference to [Fig.6], the administration module 2 further includes a fluidic path opening system 40 configured to control the drilling of the pierceable septum 24 by the drilling needle 32 and thus put the container 22 in fluidic communication with the injection needle 34 through the drilling needle 32 and the flexible tube 36.
[0087] The support member 42 is slidably mounted on a sliding guide 44 mounted on the main body 11 (Figures 9, 12 and 13). The support member 42 is movable between a first operating position in which the drilling needle 32 is spaced from the drillable septum 24 (as illustrated for example in Figures 10 and 12) and the fluidic path 30 is closed, and a second operating position in which the drilling needle 32 has pierced the drillable septum 24 (as illustrated for example in Figures 11 and 13), thus opening the fluidic path 30.
[0088] With reference to Figures 10 and 11, the displacement of the support member 42 is achieved by providing a motion transmission element 50 comprising a worm screw 54 in contact with a rack 51 at the level of a coupling part 53 of the rack 51. The latter is in turn coupled to a drive element 48 which can rotate around an axis of rotation X and which can be coupled to the support element 42.
[0089] In particular, the drive member 48 comprises a substantially circular base body 48a, a coupling portion 48b configured to couple to the support member 42, and a coupling portion 48c at which a coupling portion 52 of the rack 51 is engaged. The coupling portion 52 is disposed downstream of the coupling portion 53 along direction A.
[0090] The coupling parts 48b and 48c extend from the base body 48a on axially opposite sides with respect to the axis of rotation X.
[0091] The coupling part 48b is defined by a peripheral wall 48d. The latter is provided with a through opening 48e and delimits in the coupling part 48b a substantially cylindrical zone 48g (figures 11 and 14).
[0092] The coupling part 48c includes a toothing 48f in contact with the coupling part 52 of the rack 51 and extending circumferentially over a predetermined angle less than 360°, more preferably less than 180°, for example equal to about 90°.
[0093] As shown in [Fig. 10], the rack 51 is driven to move towards the support member 42 along a direction A orthogonal to the axis of rotation X and substantially parallel to the plane P, by the rotation of the worm screw 54 which in turn is driven in rotation by a magnetic rotor 56 (shown in full in [Fig. 2]) mounted on the main body 11 and driven by the magnetic drive rotor 9a provided in the control module 3. Due to the coupling between the rack 51 and the teeth 48f, the movement of the rack 51 causes the drive member 48 to rotate around the axis of rotation X.
[0094] As shown in [Fig. 9], the support member 42 is subjected to a pushing action along a direction B opposite to the direction A by an elastic element 46, in particular a torsion spring. This spring comprises a plurality of turns arranged around an axis orthogonal to the axis of rotation X and tends to push the support member 42 from the first operating position to the second operating position.
[0095] As shown in Figures 10, 11 and 14, the support member 42 comprises a body 42a and a stop element 43 projecting from the body 42a and dimensioned to pass through the through opening 48e. In particular, the stop element 43 is defined by a cylindrical pin 43a that extends cantilevered from the outer lateral surface of the body 42a.
[0096] Until the drive member 48 rotates around the axis of rotation X by an angle less than a predetermined value, the support member 42 remains in the first operating position due to the mutual stop between the stop element 43 and the outer surface of the peripheral wall 48d. This mutual stop counteracts the thrust action exerted by the elastic element 46 on the support member 42 ([Fig. 10]).
[0097] As soon as the angle of rotation of the drive member 48 reaches the predetermined value mentioned above, the support member 42 is free to move from the first operating position to the second operating position along the direction B because of the fact that the stop element 43 is at the level of the through opening 48e ([Fig. 11]) and can pass through it because of the pushing action exerted by the elastic element 46, so as to arrange itself in the area 48g of the coupling part 48b ([Fig. 14]).
[0098] Figures 15 to 17 depict a second embodiment of the fluidic path opening system 40, which can also be used in the device 1 of the present invention as an alternative to that described above. The elements of this second embodiment that are identical or equivalent to those described above are designated by the same numeral.
[0099] In this second embodiment, the coils of the torsion spring that defines the elastic element 46 are arranged around an axis orthogonal to the axis of rotation X and positioned closer to the rack 51 with respect to the axis of the torsion spring of the embodiment described above.
[0100] Furthermore, in the embodiment of figures 15 to 17, the stop element 43 is defined by a straight rib 43b arranged on the outer lateral surface of the body 42a.
[0101] In [Fig. 15], the drive member 48 is shown in a first angular position, while in [Fig. 16], the drive member 48 is shown in a second angular position. These angular positions are functionally similar to those in Figures 10 and 11 of the first embodiment described above.
[0102] In [Fig. 17], the drive member 48 is shown in a different angular position, posterior to that of [Fig. 16]. When the drive member reaches the angular position of [Fig. 17], the rib 43b, which has previously entered the area 48g of the coupling portion 48b ([Fig. 16]), is located at an inner surface of the peripheral wall 48d and cannot exit the area 48g. In this way, the drive member 48 prevents a possible tendency of the support member 42 to move from the second operating position to the first operating position.
[0103] As shown in [Fig. 6] and Figures 18 to 23, the administration module 2 also includes an injection needle displacement mechanism 60, configured to move the injection needle 34, at the start of therapy administration from a rest position, in which the injection needle 34 is fully arranged inside the device 1 and does not protrude from the plane P of the device 1 (Figures 18 and 19), to an injection position in which the injection needle 34 protrudes at least partially from the plane P of the device 1 (Figures 20 and 22) through the through opening 12a, and at the end of therapy administration from the injection position to the rest position ([Fig.21]).
[0104] The support member 62 which supports the injection needle 34 is movable orthogonally to the plane P between a first operating position in which the injection needle 34 is in the rest position and a second operating position in which the injection needle 34 is in the injection position.
[0105] The support member 62 has a substantially cylindrical shape and has an external lateral surface 62a to which the end part 36b of the flexible tube 36 is connected.
[0106] As shown in [Fig.23], the support member 62 is subjected to a pushing action exerted by a compression spring 64. This pushing action tends to push the support member 62 towards its first operating position, so as to maintain the injection needle 34 in the rest position before the use of the device 1 ([Fig. 18]) and to return the injection needle 34 to the rest position after the administration of the therapy ([Fig.21]).
[0107] In particular, the compression spring 64 is arranged between the main body 11 and an inner surface 62b of the support member 62 facing the plane P.
[0108] The compression spring 64 extends along an axis C orthogonal to the plane P, while the injection needle 34 extends along a distinct axis N parallel to the axis C. The axis N is arranged near the outer lateral surface 62a of the support member 62.
[0109] With reference to figures 18 to 23, the injection needle displacement mechanism 60 includes a push member 63 configured to move the support member 62 and, thus, the injection needle 34. The push member 63 can move from a first service position (figures 18 and 19) in which the support member 62 is in the first operating position and the injection needle 34 is in the rest position to a second service position (figures 20, 22 and 23) in which the support member 62 is in the second operating position and the injection needle 34 is in the injection position.
[0110] The thrust member 63 is subjected to a thrust action exerted by a compression spring 65 (Figures 22 and 23). This thrust action tends to push the thrust member 63 towards the second operating position.
[0111] The compression spring 65 is arranged between the intermediate cover 15 and a inner surface 63a of the thrust member 63 facing away from plane P.
[0112] The compression spring 65 extends along an axis D orthogonal to the plane P. The axis D is distinct from the axis C and the axis N, and parallel to them.
[0113] The compression spring 65 has a higher elastic constant than that of the compression spring 64.
[0114] The injection needle displacement mechanism 60 has two main operating configurations.
[0115] In a first operating configuration, illustrated in [Fig. 20], the thrust member 63 is coupled to the support member 62, and the force exerted by the compression spring 65 on the thrust member 63 moves it from the first operating position to the second operating position, moving the support member 62 from the first operating position to the second operating position. During the movement of the support member 62, the compression spring 64 is loaded.
[0116] In a second operating configuration, shown in [Fig. 21], the thrust member 63 is decoupled from the support member 62, and the force exerted by the compression spring 64 on the support member 62 moves it from the second operating position to the first operating position. When the injection needle displacement mechanism 60 is in the second operating configuration, the thrust member 63, which is decoupled from the support member 62, remains in the second operating position due to the thrust action exerted by the compression spring 65.
[0117] The thrust member 63 has a substantially cylindrical shape and is movable in rotation about the axis D from a first angular position ([Fig.20]) in which the injection needle displacement mechanism 60 is in the first operating configuration to a second angular position ([Fig.21]) in which the injection needle displacement mechanism 60 is in the second operating configuration.
[0118] A stop element 62c (visible in [Fig.21]) extends from the outer lateral surface 62a of the support member 62 towards the thrust member 63 and a thrust element 63c extends from an outer lateral surface 63b of the thrust member 63 towards the support member 62.
[0119] When the injection needle displacement mechanism 60 is in the first operating configuration, the push element 63c is coupled to the stop element 62c and exerts a push action against the latter ([Fig.20]), whereas, when the injection needle displacement mechanism 60 is in the second operating configuration, the push element 63c is decoupled from the stop element 62c ([Fig.21]).
[0120] The rotation of the thrust member 63 from the first angular position to the second angular position, and consequently the transition of the injection needle displacement mechanism 60 from the first operating configuration to the second operating configuration, is driven by an instruction member 61 arranged concentrically to and outside the thrust member 63.
[0121] The instruction member 61 has a substantially cylindrical shape and is driven to rotate about the axis D initially from an angular stop position ([Fig.18]) in which the thrust member 63 is in the first angular position and the instruction member 61 is coupled to the thrust member 63 and maintains the latter in the first service position, to a first angular release position ([Fig.20]) in which the thrust member 63 is still in the first angular position and the instruction member 61 is decoupled from the thrust member 63 allowing the thrust member 63 to reach the second service position.
[0122] A projecting element 63d extends from the outer lateral surface 63b of the thrust member 63 on the opposite side with respect to the thrust member 63c.
[0123] The instruction member 61 includes a stop surface 61e which, when the instruction member 61 is in the angular stop position, is abutted against the projecting element 63d (figures 18 and 19).
[0124] The instruction member 61 further includes a seat 61a which, when the instruction member 61 is in the first angular release position, houses the projecting element 63d ([Fig.20]), and a through opening 61b ([Fig.18]) through which the thrust element 63c passes to allow the thrust member 63 to couple with the support member 62.
[0125] When, following the rotation of the instruction member 61, the seat 61a is below the protruding element 63d, the thrust member 63 is free to move from the first service position to the second service position due to the thrust action exerted by the compression spring 65. Consequently, the support member 62 is moved from the first operating position to the second operating position due to the movement of the thrust member 63 from the first service position to the second service position and, therefore, due to the thrust exerted by the thrust element 63c on the stop element 62c, this thrust no longer being hindered by the stop surface 61e of the instruction member 61. The injection needle 34 is thus extracted from the device 1.
[0126] The thrust element 63c passes through the through opening 61b of the instruction member 61 both when the thrust member 63 is in the first service position and when the thrust member 63 is in the second service position.
[0127] Next, the instruction member 61 is rotated about the axis D from the first angular release position ([Fig.20]) to a second position angular release ([Fig. 21]) in which the thrust member 63 is in the second angular position. This rotation causes a similar rotation of the thrust member 63 because the projecting element 63d is housed in the seat 61a.
[0128] The housing of the protruding element 63d in the seat 61a therefore allows both the transition of the push member 63 from the first service position to the second service position due to the push exerted on the push member 63 by the compression spring 65, with the consequent extraction of the injection needle 34 from the device 1 ([Fig.20]), and the transfer of the rotary motion of the instruction member 61 to the push member 63 when it is in the second service position ([Fig.21]), with the consequent release of the support member 62 by the push member 63 and the consequent retraction of the injection needle 34 inside the device 1 due to the push exerted on the support member 62 by the compression spring 64.
[0129] The instruction member 61 includes a coupling part 61c in contact with the worm screw 54. The coupling part 61c is a toothing circumferentially extended over a predetermined angle, preferably less than 180°.
[0130] As shown in [Fig.22], a suitably shaped plate 630 is arranged above the thrust member 63 and the support member 62 to prevent rotation of the thrust member 63 around the axis D. This plate 630 also allows all the components of the injection needle displacement mechanism 60 to be aligned and ensures the retention of the compression springs 64 and 65 along the direction of the axis D.
[0131] As shown in Figures 7, 8, 22 to 24, the delivery module 2 also includes a protective element 70 arranged around the injection needle 34 and configured to cover the tip of the injection needle 34 if the latter is in the injection position, or moves into it, for example due to a malfunction or failure of the injection needle movement mechanism 60, before applying the device 1 to the patient's skin, or if the injection needle 34 accidentally remains in the injection position when removing the device 1 from the patient's skin, for example due to accidental or voluntary removal by the patient before the end of the therapy administration ([Fig.23]).
[0132] The protective element 70 is movable between a first operating position (Figures 7 and 23) in which it protrudes from the device 1 and covers the tip of the injection needle 34 if the injection needle 34 is in the injection position ([Fig.23]), and a second operating position (Figures 8 and 22) in which it does not protrude from the device 1.
[0133] The protective element 70 is shown in detail in [Fig.24].
[0134] The protective element 70 is subjected to a pushing action exerted by an elastic element 72, in particular by a compression spring. This pushing action tends to maintain the protective element 72 in the first operating position both before applying the device 1 to the patient's skin and when the device 1 is removed from the patient's skin ([Fig. 7]) and to allow the protective element 70 to reach the second operating position when the device 1 is applied to the patient's skin (Figures 8 and 22).
[0135] In particular, the elastic element 72 is arranged between the intermediate cover 15 and an inner surface 70e which is inside the protective element 70 and which is turned towards the intermediate cover 15 (figures 22 and 23).
[0136] The elastic element 72 extends along an axis E orthogonal to the plane P. The axis E is distinct from the axes C, D and N, and parallel to them.
[0137] With reference to [Fig.6], the administration module 2 includes a stop mechanism 170 configured to stop the movement of the protection element 70.
[0138] In particular, the protective element 70 includes a locking element 70b configured to lock the protective element 70 in the first operating position when the device 1 is removed from the patient's skin. The locking of the protective element 70 occurs when the locking element 70b interferes with a stop element 74 associated with the rack 51 at a coupling portion 55 of the rack 51 which is arranged upstream with respect to the coupling portion 52 and downstream with respect to the coupling portion 53 along direction A, i.e. interposed between the coupling portion 53 and the coupling portion 52 (Figures 20 and 21).
[0139] The device 1 has a reversible initial configuration in which the protective element 70 is free to move between the first operating position and the second operating position and vice versa before the device 1 is applied to the patient's skin. In this configuration, the locking element 70b, which is integral with the protective element 70, is in a distal position relative to the stop element 74.
[0140] The device 1 has an irreversible final configuration in which the protective element 70 is locked in the first operating position. In this configuration, the locking element 70b is in contact with the stopping element 74.
[0141] Due to the movement of the rack 51 along direction A, the stop element 74 moves along this direction A from an initial position to a final position.
[0142] In the initial position, the stop element 74 and the locking element 70b are not superimposed on each other and the device 1 is in the initial reversible configuration (Figures 18 and 19), while in the final position, the stop element 74 and the locking element 70b are superimposed on each other and device 1 is in the final irreversible configuration (figures 20 and 21).
[0143] Preferably, the locking element 70b is made of a rigid material and the stopping element 74 is made of a deformable material.
[0144] The switch from the reversible to the irreversible configuration occurs when the stop element 74 is in the final position and the locking element 70b moves along a direction F ([Fig.23]) orthogonal to the direction A, passing beyond the stop element 74. This movement occurs when the device 1 is removed from the patient's skin due to the movement of the protective element 70 from the second operating position to the first operating position due to the pushing action exerted by the elastic element 72.
[0145] The movement of the locking element 70b along the direction F first causes interference between the locking element 70b and the stop element 74, then the transition of the locking element 70b to the opposite side of the stop element 74 due to the deformation of the latter.
[0146] In particular, the stopping element 74 comprises a first surface turned away from plane P and a second surface turned towards plane P.
[0147] The first surface allows the deformation of the stop element 74 as a consequence of the interference with the locking element 70b and the displacement of the locking element 70b along the direction F from the second operating position to the first operating position.
[0148] The first surface is preferably inclined with respect to a plane orthogonal to the direction F, thus facilitating the transition of the locking element 70b from one side to the other side of the stop element 74 as a consequence of the deformation of the latter.
[0149] The second surface instead defines a notch which, when the device 1 is in the final irreversible configuration, prevents the locking element 70b from moving from the first operating position. The second surface is preferably orthogonal to the direction F.
[0150] As shown in [Fig.24], the protective element 70 has a base 70a provided with a through hole 71 to allow the transition of the injection needle 34 during the movement of the injection needle 34 between the rest position and the injection position when the protective element 70 is in the second operating position.
[0151] The base 70a includes a raised edge 70b defining in the base 70a a recess 70c which houses the tip of the injection needle 34 both when the protective element 70 is in its second operating position and the injection needle 34 is in the rest position ([Fig. 8]) and when the protective element 70 is in its first operating position and the injection needle 34 is in the position injection ([Fig.23]).
[0152] As shown in Figures 33 and 34, the through hole 71 can be closed by a drillable septum 271.
[0153] Device 1 includes a position sensor 76 (Figures 7 and 8) adapted to detect contact of device 1 with the patient's skin.
[0154] The position sensor 76 includes a magnet 77 associated as one with the protective element 70 and a Hall effect sensor 78 disposed in the control module 3 near the magnet 77.
[0155] The magnet 77 is entirely housed in a seat 75 formed in the protective element 70 ([Fig.24]).
[0156] The locking element 70b is associated with the seat 75 near the magnet 77.
[0157] As shown in Figures 2 and 5, the device 1 further comprises a flexible sleeve 80 associated in a watertight manner to the application surface 12 of the administration module 2 around the through opening 12a.
[0158] The flexible sleeve 80 is made of a medical-grade silicone material.
[0159] The flexible sleeve 80 surrounds the protective element 70 and comprises a surface base 80a having an inner surface joined in one piece with the outer surface of base 70a of the protective element 70.
[0160] In the embodiment illustrated here, the flexible sleeve 80 is defined by a bellows-type membrane having a truncated cone shape.
[0161] The flexible sleeve 80 is disposed entirely inside the administration module 2 when the protective element 70 is in its second operating position ([Fig.8]).
[0162] The base surface 80a of the flexible sleeve 80 covers the through hole 71 of the protective element 70 and can be pierced by the injection needle 34 when the injection needle 34 moves from the rest position to the injection position.
[0163] The flexible sleeve 80 includes an annular end portion 83 fixed to the application surface 12 of the delivery module 2 by means of a compression ring 83a (Figures 23, 33 and 34). The latter is welded to the application surface 12 by ultrasonic welding.
[0164] The annular end part 83 is thus interposed between the application surface 12 and the compression ring 83a and prevents water and powders from entering the inside of the device 1 via the through opening 12a of the application surface 12.
[0165] As shown in Figures 4 and 5, a patch 90 is applied to the application surface 12 of the main body 11 of the administration module 2.
[0166] The patch 90 comprises an adhesive layer 91 fixed in one piece to the application surface 12 and a protective layer 92 removably fixed to the adhesive layer 91. Before administering the therapy, the protective layer 92 is removed ([Fig.5]) and device 1 is fixed to the patient's skin through adhesive layer 91.
[0167] The device 1 further includes a cap 100 fixed in one piece to the protective layer 92. In particular, the cap 100 includes a collar 101 fixed to the protective layer 92 by interposition of a double adhesive element 101a.
[0168] The cap 100 is made of a rigid material and is shaped to completely house, with some clearance, the protective element 70 and the flexible sleeve 80 which surrounds the protective element 70 when the latter is in its first operating position.
[0169] In the embodiment illustrated here, the cap 100 has a frustoconical shape.
[0170] As already mentioned, the protective element 70 is initially in its extended configuration of [Fig. 5] and the cap 100 covers the protective element 70, as shown in [Fig. 4].
[0171] Before applying the device 1 to the patient's skin, the patient removes the protective layer 92 from the patch 90, simultaneously removing the cap 100 with it and thus exposing the protective element 70 and the adhesive layer 91 of the patch 90.
[0172] The patient can then proceed to apply the device 1 to his skin by fixing it through the adhesive layer 91 of the patch 90. The patient's skin counteracts the pushing action exerted by the elastic element 72 and causes the protective element 70 to retract inside the delivery module 2, bringing the magnet 77 closer to the Hall effect sensor 78 and thus allowing the control unit 7 to establish that the device 1 is in contact with the patient's skin and to activate the administration of the therapy.
[0173] The administration of the therapy includes the controlled movement of the piston 26 inside the container 22 towards the pierceable septum 24. For this purpose, the administration module 2 includes a drug delivery mechanism 110 ([Fig.6]) which is activated, driven by the control unit 7, by the same magnetic rotor 56 which drives the motion transmission member 50 and, consequently, the rotation of the worm gear 54. As already mentioned, the latter drives both the activation of the injection needle movement mechanism 60 and the movement of the rack 51 along the direction A, which in turn drives both the opening of the fluidic path 30 and the locking of the protective element 70 in the first operating position after the removal of the device 1 from the patient's skin.
[0174] In particular, the control unit 7 drives the magnetic rotor 56 alternately in a first direction of rotation to activate the motion transmission member 50 and in a second direction of rotation opposite to the first direction of rotation to drive the administration of the drug from the container 22 when another motion transmission member 111 is activated ( [Fig.6]) arranged in the main body 11 on the side opposite the motion transmission member 50 relative to the magnetic rotor 56 and the worm gear 54.
[0175] Figures 25 to 34 show another embodiment of a device which differs from device 1 described above with respect to certain details relating to the injection needle displacement mechanism 60, the protective element 70 and the flexible sleeve 80. The elements and / or components of this embodiment which are identical or equivalent to those described above are indicated by the same numerical reference.
[0176] In this case, the flexible sleeve 80 does not have the base surface 80a and the protective element 70 has a base 70a having a diameter greater than that of the adjacent end part of the flexible sleeve 80.
[0177] Also in this case, a support member 62 which supports the injection needle, a push member 63 and an instruction member 61 equivalent to those described above are provided.
[0178] Fig. 25 shows the operating configuration in which the injection needle 34 is in the rest position and the protective element 70 and the flexible sleeve 80 protrude from the device.
[0179] Figures 26 and 33 show the operating configuration in which the device is applied to the patient's skin. The injection needle 34 is always in the resting position, and the protective element 70 and the flexible sleeve 80 are pushed inside the device. Only the base 70a of the protective element 70 remains protruding from the device.
[0180] Figure 28 shows the operating configuration in which the device is applied to the patient's skin and the injection needle 34 is in the injection position to administer the therapy. The protective element 70 and the flexible sleeve 80 are always inside the device.
[0181] Fig. 30 shows the operating configuration in which the device is still applied to the patient's skin, but the injection needle 34 has been returned to the resting position.
[0182] Figure 31 shows the operating configuration in which the device is removed from the patient's skin at the end of therapy administration. The protective element 70 and the flexible sleeve 80 protrude from the device.
[0183] Figures 32 and 34 show the operating configuration in which the device is removed from the patient's skin before the end of therapy administration and the injection needle 34 is still in the injection position. The protective element 70 and the flexible sleeve 80 protrude from the device, and the protective element 70 is locked in position outside the device.
[0184] In this embodiment, the instruction member 61 comprises two articulated arms 631 arranged on opposite sides with respect to the thrust element 63c ([Fig.27]). As illustrated in [Fig. 29], each articulated arm 631 comprises a first lever 631a articulated on the outer lateral surface 61g of the instruction member 61 and a second lever 631b articulated on the first lever 631a. Each second lever 631b is slidably coupled to a respective guide 633 and comprises a respective stop element 174 whose shape and material are similar to those of the stop element 74 described previously.
[0185] The protection element 70 comprises two locking elements 171 arranged on diametrically opposite sides with respect to the stop element 62c and configured to cooperate with the stop elements 174 ([Fig.27]).
[0186] During the rotation of the instruction member 61, the stop elements 174 approach the respective locking elements 171 until each of them is at the level of the respective locking element 171.
[0187] In the operating configuration of figures 25 to 30, the two locking elements 171 are arranged on one side relative to the stopping elements 174, in particular near the shaped plate 630. This is because the protective element 70 does not protrude from the device.
[0188] When the protective element 70 is removed from the device following its removal from the patient's skin, the locking elements 171 pass beyond the stop elements 174, locking the protective element 70 in the position shown in [Fig. 31]. In this operating configuration, the injection needle 34 has been previously retracted into the device.
[0189] If, after removal of the device from the patient's skin, the injection needle 34 remains outside the device, as in the operating configuration of [Fig.32], the protective element 70 and the flexible sleeve 80 protect the patient from any contact with the injection needle 34.
[0190] With reference also to [Fig.35], the sequence of operating steps implemented by device 1 during its use is described in detail below.
[0191] During a first time interval preceding the instant t0 when the patient activates the device 1 by pressing the activation button 3a, the patient separately receives the administration module 2 and the control module 3 and pairs them. During this time interval, the device 1 is in standby mode, i.e., the power supply battery 8 powers only some of the electronic components in the control module 3 through a hardware unit that cuts off the power supply to all electronic components except those associated with: the ignition magnet 2a, the switch that powers the control unit 7, the activation button 3a for activating the device 1, and the NFC tag 2b. The motor 9 is not powered.
[0192] After mutual coupling, the administration module 2 and the control module 3 are temporarily coupled not only mechanically but also magnetically by means of a coupling established by the proximity between the magnetic drive rotor 9a provided in the control module 3 and the magnetic rotor 56 provided in the administration module 2. The control unit 7 is energized by a change in the magnetic field generated by the mutual approach between the ignition magnet 2a and the switch that powers the control unit 7, which are closer together. This mutual approach triggers the aforementioned switch, which energizes the control unit 7.
[0193] Once powered on, the control unit 7 performs a self-diagnostic.
[0194] Furthermore, after power-up, the control unit 7 queries the NFC tag 2b by reading the information stored therein. In particular, the control unit 7 performs any or all of the following actions: checking whether the administration module 2 has already been used, checking whether the administration module 2 is configured to administer a correct dosage of the drug, establishing the drug administration procedure, establishing the drug administration rate.
[0195] After power-up, the control unit 7 also reads the signal from the position sensor 76 to determine if the device 1 is in contact with the patient's skin.
[0196] In particular, the patient removes the protective layer 92 from the patch 90, simultaneously removing the cap 100 with it, and applies the device 1 to his skin.
[0197] In the time interval mentioned above preceding time t0 and before the application of device 1 to the patient's skin: - the fluidic path 30 is closed, that is to say that the drilling needle 32 is in a distal position relative to the perforatable septum 24 and the elastic element 46 is compressed; - the protective element 70 is in its first operating position, i.e. it protrudes from the device 1 and the elastic element 72 is extended; - due to the distance between the magnet 77 and the Hall effect sensor 78, the position sensor 76 signals to the control unit 7 that the device 1 has not yet been applied to the patient's body; - the injection needle displacement mechanism 60 is deactivated, i.e. the injection needle 34 is in the rest position, inside the device 1; - the flexible sleeve 80 is extended.
[0198] In the time interval mentioned above preceding time t0, after application of device 1 to the patient's skin: - the fluidic path 30 remains closed; - the protective element 70 is in its second operating position, i.e. it is arranged inside the device 1 and the elastic element 72 is compressed; - due to the mutual approach between the magnet 77 and the Hall effect sensor 78, the position sensor 76 signals to the control unit 7 that the device has been applied to the patient's body and that the control unit 7 can be activated for the administration of the therapy; - the injection needle displacement mechanism 60 remains deactivated; - the flexible sleeve 80 is folded inside the device 1.
[0199] If the control unit 7 does not detect the signal from the position sensor 76 within a predetermined time, the control unit 7 switches off and the device 1 returns to standby mode.
[0200] At this stage (i.e. at time t0), the device 1 is put into operation by the patient by pressing the activation button 3a. The motor 9 is activated and the control unit 7 orders a series of operations which require no action on the part of the patient.
[0201] In a time interval tl following the time t0 and which lasts for example 10 to 15 seconds, the magnetic rotor 56 is set in rotation in the first direction of rotation by the motor 9 and activates the motion transmission member 50, which in turn simultaneously activates the fluidic path opening system 40 (the drilling needle 32 pierces the pierceable septum 24 and the elastic element 46 extends) and the injection needle displacement mechanism 60 without however moving the injection needle 24, which remains in the rest position.
[0202] In particular, the rotation of the worm gear 54 causes the rack 51 to move along direction A and the resulting rotation of the drive member 48 and the opening of the fluidic path 30. This rotation also causes the instruction member 61 to rotate, moving it from the angular stop position shown in [Fig. 18] to another angular stop position, shown in [Fig. 19]. This rotation does not cause the thrust member 63 to rotate; it remains in its initial operating position because the projecting element 63d remains abutted against the thrust surface 61e.
[0203] In a time interval t2 following the time interval t1, lasting for example 8 to 12 seconds, the magnetic rotor 56 is rotated in the second direction of rotation by the motor 9 and activates the motion transmission member 111, causing the piston 26 to move inside the container 22. This movement causes the drug to exit through the piercing needle 32, but not to be administered through the injection needle 34. The thrust The pressure exerted by the piston 26 on the drug causes the air contained in the fluidic path 30 to exit (priming phase).
[0204] In a time interval t3 following the time interval t2 and lasting for example 8 to 12 seconds, the magnetic rotor 56 is put back into rotation in the first direction of rotation by the motor 9 and again activates the motion transmission member 50, causing the reactivation of the injection needle displacement mechanism 60.
[0205] In particular, the rotation of the worm gear 54 causes an additional rotation of the instruction member 61, which moves from the angular stop position of [Fig. 19] to the first angular release position of [Fig. 20]. This rotation causes the thrust member 63 to move from the first operating position to the second operating position and, consequently, the support member 62 (and therefore the injection needle 34) to move from the first operating position (injection needle 34 in the rest position) to the second operating position (injection needle 34 in the injection position). The injection needle 34 thus penetrates the patient's skin.
[0206] In a time interval t4 following the time interval t3 and lasting for example 2 to 5 seconds, the magnetic rotor 56 is again set in rotation in the second direction of rotation by the motor 9 and again activates the motion transmission member 111, causing the movement of the piston 26 inside the container 22 which this time causes the administration of the drug into the patient's body through the injection needle 34. In this phase, it may still happen that a very limited quantity of air, which remained inside the fluidic path 30 after the priming phase, is expelled from the fluidic path.
[0207] Following the time interval t4, the motor 9 again drives the magnetic rotor 56 in the first direction of rotation by reactivating the motion transmission member 50 and causing the reactivation of the injection needle displacement mechanism 60.
[0208] In particular, the rotation of the worm gear 54 causes an additional rotation of the instruction member 61, which moves from the first angular release position of [Fig. 20] to the second angular release position of [Fig. 21]. This rotation causes a similar rotation of the thrust member 63 because the protruding element 63d is housed in the seat 61a and, consequently, the thrust member 63c is decoupled from the stop element 62c. At this point, the force exerted by the compression spring 64 on the support member 62 moves it from the second operating position to the first operating position, leaving the thrust member 63 in the second operating position. The injection needle 34 thus returns to its rest position, i.e., inside the device 1.
[0209] The control unit 7 emits an end-of-therapy signal n seconds after causing the instruction organ 61 to move from the first angular release position of [Fig.20] to the second angular release position of [Fig.21], in order to ensure that the patient can remove the device from their skin when the injection needle 34 has returned to the resting position, i.e., it is inside the device 1.
[0210] The emission of the end-of-therapy signal by the control unit is communicated to the patient by visual and / or acoustic signals.
[0211] The patient can then remove device 1 from their skin.
[0212] Removing the device 1 from the patient's body causes the protective element 70 (and consequently the flexible sleeve 80) to move from the second operating position (protective element 70 inside the device 1 and the flexible sleeve 80 folded inside the device 1) to the first operating position (protective element 70 outside the device 1 and the flexible sleeve 80 extended outside the device 1) due to the pressure exerted on the protective element 70 by the elastic element 72 and, consequently, locks the protective element 70 in the first operating position due to the movement of the locking element(s) 70b, 171 from one side to the other of the stop element(s) 74, 174 and the stop between the locking element(s) 70b, 171 and the second surface of the stop element 74, 174 rotated towards plan P.
Claims
Claims
1. A device (1) for subcutaneous administration of a medicament, comprising: - an injection needle (34) configured to inject the medicament into a patient when the device (1) is applied to the patient's skin, the injection needle (34) being movable between a rest position in which the injection needle (34) is entirely disposed within the device (1) and an injection position in which the injection needle (34) protrudes at least partially from the device (1) through a through opening (12a) of the device (1); - a protective element (70) disposed around the injection needle (34) and movable between a first operating position in which the protective element (70) protrudes from the device (1) and a second operating position in which the protective element (70) does not protrude from the device (1);- a flexible sleeve (80) associated in a watertight manner with the device (1) around said through opening (12a) and associated in one piece with the protective element (70).;
2. Device (1) according to claim 1, wherein the protective element (70) comprises a base (70a) provided with a through hole (71) to allow the passage of the injection needle (34) during the movement of the injection needle (34) between the rest position and the injection position and wherein the flexible sleeve (80) is integrally associated with said base (70a).
3. Device (1) according to claim 2, wherein the flexible sleeve (80) is defined by a membrane having an inner surface which is integrally associated with the outer surface of said base (70a).
4. Device (1) according to claim 3, wherein said membrane is of the bellows type and has a substantially conical or truncated cone shape.
5. Device (1) according to any one of claims 2 to 4, wherein the flexible sleeve (80) has a base surface (80a) integrally associated with the base (70a) of said protective element (70) and wherein said base surface (80a) covers said through hole (71) and can be pierced by the injection needle (34) when the injection needle (34) passes from the rest position to the injection position.
6. Device (1) according to any one of claims 2 to 4, wherein the through hole (71) of the base (70a) of the protective element (70) is closed by a pierceable septum (171) configured to be pierced by the injection needle (34) when the injection needle (34) passes from the rest position to the injection position.
7. Device (1) according to any one of the preceding claims, wherein said flexible sleeve (80) is entirely arranged inside said device (1) when said protective element (70) is in its second operating position.
8. Device (1) according to any one of the preceding claims, comprising a compression ring (83a) welded to an application surface (12) of the device (1) at said through opening (12a) and wherein said flexible sleeve (80) comprises an annular end portion (83) which is interposed between said application surface (12) and said compression ring (83a).
9. Device (1) according to claim 8, wherein said compression ring (83a) is welded by ultrasonic welding.
10. A device (1) according to any preceding claim, wherein said flexible sleeve (80) is made of a medical grade silicone material.
